Oaktree Acquisition Corp. III Life Sciences (OACC) Non-Current Deffered Revenue (2024 - 2026)
Oaktree Acquisition Corp. III Life Sciences filings provide 3 years of Non-Current Deffered Revenue readings, the most recent being $6.7 million for Q1 2026.
- Quarterly Non-Current Deffered Revenue changed 0.0% to $6.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $6.7 million for FY2025, 0.0% changed from the prior year.
- Non-Current Deffered Revenue hit $6.7 million in Q1 2026 for Oaktree Acquisition Corp. III Life Sciences, roughly flat from $6.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $6.7 million in Q4 2024 and bottomed at $6.7 million in Q4 2024.
- Average Non-Current Deffered Revenue over 3 years is $6.7 million, with a median of $6.7 million recorded in 2024.
- Peak annual rise in Non-Current Deffered Revenue hit 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
- Oaktree Acquisition Corp. III Life Sciences' Non-Current Deffered Revenue stood at $6.7 million in 2024, then changed by 0.0% to $6.7 million in 2025, then changed by 0.0% to $6.7 million in 2026.
- Per Business Quant, the three most recent readings for OACC's Non-Current Deffered Revenue are $6.7 million (Q1 2026), $6.7 million (Q4 2025), and $6.7 million (Q3 2025).